PNH-RECORD
Real-life treatment outcomes of ravulizumab in Polish patients with paroxysmal nocturnal hemoglobinuria (PNH). Prospective and retrospective, multicenter, non-interventional study.
Dear Madam/Sir
We would like to invite you to participate in a multicenter, observational, open-label study designed to document the management and clinical outcomes of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) that received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program. The registration and login panel for the eCRF system is available on the right
We would like to invite you to participate in a multicenter, observational, open-label study designed to document the management and clinical outcomes of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) that received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program. The registration and login panel for the eCRF system is available on the right
Please log in with your details received after the conclusion of the contract.
530 900 803 
